ID: ALA4291325

Max Phase: Preclinical

Molecular Formula: C21H36N2O8

Molecular Weight: 444.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCC(=O)NC[C@@H](O)[C@@H](O)[C@@H]1OC(C(=O)O)=C[C@H](O)[C@H]1NC(=O)CCCCC

Standard InChI:  InChI=1S/C21H36N2O8/c1-3-5-7-9-16(26)22-12-14(25)19(28)20-18(23-17(27)10-8-6-4-2)13(24)11-15(31-20)21(29)30/h11,13-14,18-20,24-25,28H,3-10,12H2,1-2H3,(H,22,26)(H,23,27)(H,29,30)/t13-,14+,18+,19+,20+/m0/s1

Standard InChI Key:  KBYKSOPUIHFIQP-WHHUABKHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 444.53

Molecular Weight (Monoisotopic): 444.2472

AlogP: 0.20

#Rotatable Bonds: 14

Polar Surface Area: 165.42

Molecular Species: ACID

HBA: 7

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.20

CX Basic pKa:

CX LogP: 0.09

CX LogD: -3.35

Aromatic Rings: 0

Heavy Atoms: 31

QED Weighted: 0.21

Np Likeness Score: 0.69

References

1. Guo T, Héon-Roberts R, Zou C, Zheng R, Pshezhetsky AV, Cairo CW..  (2018)  Selective Inhibitors of Human Neuraminidase 1 (NEU1).,  61  (24): [PMID:30457869] [10.1021/acs.jmedchem.8b01411]

2.  (2018)  Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data